|
Jul 17
|
Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
|
|
Jul 16
|
High Growth Tech Stocks In Asia With Promising Potential
|
|
Jul 16
|
FDA invites more data from abroad — with a wary eye on China
|
|
Jul 3
|
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 47.8%
|
|
Jun 24
|
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
|
|
Jun 22
|
Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
|
|
Jun 17
|
High Growth Tech Stocks in Asia Featuring 3 Promising Picks
|
|
Jun 16
|
/C O R R E C T I O N -- Innovent Biologics/
|
|
Jun 13
|
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
|
|
May 29
|
Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
|
|
May 26
|
Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
|
|
May 19
|
High Growth Tech Stocks To Watch In May 2025
|
|
May 19
|
Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation
|
|
May 16
|
Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)
|
|
Apr 15
|
High Growth Tech Stocks In Asia For April 2025
|
|
Feb 17
|
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
|
|
Jan 3
|
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
|
|
Jan 2
|
Innovent and Roche link on lung cancer therapy development
|
|
Jan 1
|
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
|
|
Oct 11
|
High Growth Tech Stocks In Hong Kong October 2024
|